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Metastasis remains the most common cause of death in cancer patients. Inhibition of metalloproteinases (MMPs) is an interesting
approach to cancer therapy because of their role in the degradation of extracellular matrix (ECM), cell-cell, and cell-ECM
interactions, modulating key events in cell migration and invasion. Herein, we show the cytotoxic and antimetastatic effects
of the third fraction (FR3) from Bauhinia variegata candida (Bvc) stem on human cervical tumor cells (HeLa) and human
peripheral bloodmononuclear cells (PBMCs). FR3 inhibitedMMP-2 andMMP-9 activity, indicated by zymogram.This fractionwas
cytotoxic to HeLa cells and noncytotoxic to PBMCs and decreased HeLa cell migration and invasion. FR3 is believed to stimulate
extrinsic apoptosis together with necroptosis, assessed by western blotting. FR3 inhibitedMMP-2 activity in the HeLa supernatant,
differently from the control.The atomic mass spectrometry (ESI-MS) characterization suggested the presence of glucopyranosides,
D-pinitol, fatty acids, and phenolic acid. These findings provide insight suggesting that FR3 contains components with potential
tumor-selective cytotoxic action in addition to the action on the migration of tumor cells, which may be due to inhibition of
MMPs.
1. Introduction
Cervical cancer (CC) is the fourth most frequent type
of neoplasm among women in the worlds and the main
cause of cancer-related death in low- and middle-income
countries [1]. In 2012, more than 270,000 CC deaths occurred
worldwide [2]. Human papilloma virus (HPV) is the main
etiologic infectious agent associatedwith cervical cancer. 70%
of cases of cervical cancer are induced by HPV types 16 and
18, but over 200 types of HPV have been identified [3]. HPV
interferes with the cell cycle regulation because it infects the
cervical mucosa and integrates its genome in cells. The viral
E6 and E7 oncoproteins are critical for inducing malignant
transformation because they lead to the suppression of p53
and pRB, fundamental tumor suppressor genes. Persistent
infection leads to cervical intraepithelial neoplasia (CIN),
which, if untreated, may progress to cancer cervical [4].
Metastasis is the main cause of cancer death [5]. One
of the first steps in the metastatic cascade includes the
intravasation of tumor cells into the circulation, and the
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processes correlated with this event, such as migration and
cell invasion, are dependent on the tumor microenviron-
ment [6]. Cytoskeletal rearrangements, combined with the
degradation of cell-cell and cell-extracellular matrix (ECM)
interactions, are themainmechanisms of premetastatic tissue
remodeling [7]. ECMmetalloproteinases (MMPs), especially
MMP-2 and MMP-9, cleave ECM components, degrade the
basement membrane, and allow tumor cells to penetrate the
adjacent matrix stroma [8].This type of remodeling has been
associatedwith invasiveCCs [9] and overexpression ofMMP-
2 and MMP-9 is also correlated with a worse prognosis in
patients with this tumor type [10].
The lack of improvement in cervical cancer treatment
is mainly due to resistance to cytotoxic agents [11]. Thus,
the search for new therapies with low cost and minimal
side effects has become paramount, with many researchers
looking for compounds with anticancer activity from natural
compounds [12]. Recent studies by our research group have
shown thatBauhinia ungulata extract fractions have potential
antimetastatic activity [13].
In the present work, we characterized phytochemically a
B. variegata candida fraction with inhibitory activity against
MMPs and established the mechanism of action of these
compounds on cell viability in human cervical carcinoma
(HeLa) and human peripheral blood mononuclear cells
(PBMCs). Migration and invasion, MMP-2 activity, and the
cell death pathways of HeLa cells treated with this fraction
were also evaluated.
2. Materials and Methods
2.1. Sample and Preparation of Extracts. Bauhinia variegata
candida (Bvc) stems were collected from an urban area
of Divino´polis, Brazil, 20∘08󸀠20󸀠󸀠S; 44∘53󸀠02󸀠󸀠W; 712m, and
powdered. The powdered material (100 g) was extracted with
70% ethanol (600mL, five times) for seven days at room
temperature to obtain the crude extract. The crude extract
was partitioned using hexane, ethyl acetate, and chloroform
(160mL, each). From this, the ethyl acetate partition (PA)
was fractionated by open chromatographic column (silica gel
60G).The columnwas eluted with hexane, dichloromethane,
ethyl acetate, methanol, and water (50/50, v/v), obtain-
ing seven fractions. All extracts were frozen (−80∘C) and
lyophilized.
2.2. Cancer Cell Line, Cell Culture Conditions, and Antibodies.
Human cervical adenocarcinoma cells (HeLa) were main-
tained in Dulbecco’s Modified Eagle Medium (DMEM) sup-
plemented with 10% (v/v) heat inactivated fetal bovine serum
(SBF) and 1% streptomycin/penicillin (v/v) and maintained
in a humidified atmosphere of 5% CO
2
at 37∘C [14]. The
commercial cell line HeLa was authenticated by STR analysis
and tested for mycoplasma contamination by PCR [15]. The
DMEM culture medium, (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) (MTT), Ficoll-Paque Plus,
and MMP-2 and MMP-9 (M9445 and M8945, resp.) were
purchased from Sigma Aldrich (St. Louis, Missouri, USA).
Fetal bovine serum and Bioacoats were purchased from
Becton Dickinson (BD) (Bedford, MA, USA). Antibodies
were purchased from Cell Signaling Technology (Danvers,
Massachusetts, USA).
2.3. Peripheral Blood Mononuclear Cells. Peripheral blood
mononuclear cells (PBMCs) were isolated from fresh blood
(40mL) obtained by venipuncture from two healthy vol-
unteers. The obtained blood was centrifuged by density
gradient using Ficoll-Paque Plus. The isolated cells were
suspended in DMEM culture medium (10% FBS and 1%
v/v). Adherent cells were consideredmononuclear leukocytes
[16]. This work was approved by the Ethics Committee
in Research with Human Beings of the Federal Univer-
sity of Sa˜o Joa˜o del-Rei, under the number of opinions:
2.007.582.
2.4. Zymography. Each fraction of B. variegata candida was
diluted in dimethyl sulfoxide (DMSO 1%) and applied 90 𝜇g/
mL in each well to 10% SDS-polyacrylamide gel containing
1mg/ml gelatin, along with 1.8 𝜇g/mL of MMP-2 and MMP-
9 diluted in sample buffer (2.5% SDS and 1 g% sucrose).
Electrophoresis was performed under reducing conditions
according to [13]. Photographs of the gels were obtained
and the MMPs activities, indicated by clear bands, were
quantified by densitometry (ImageJ1.42q/Java1.6.0-10). The
fraction capable of totally inhibiting the gelatinolytic activ-
ity of MMP-2 and MMP-9 was directed to subsequent
tests.
For analysis of active MMP-2 in the cell culture super-
natant, 5 × 105HeLa cells/well were plated in a 24-well plate
and incubated for 24 hours. The cells were treated with
DMEM (2% FBS) with or without the selected fraction (IC
50
concentration). After 24 hours, the cell culture medium was
collected, lyophilized, and diluted in sample buffer (2 : 1, v/v).
In each well, 20𝜇g/proteins were applied and electrophoresis
conducted under the same conditions.
2.5. Cell Viability Assay. Cell viability was determined by
MTT assay. Hela and PBMCs cells were plated in 96-
well plates (2.5 × 105 cells/100 𝜇l/well) and incubated in 5%
CO
2
, at 37∘C. After incubation for 24 h the medium was
removed, and cells were treated with 5, 10, 25, and 50𝜇g/ml
of the fraction for 72 h. Then, 100𝜇L of DMEM with MTT
(2.5mg/mL) was added to each well and cells were incubated
at 37∘C for 3 h. After this time, the formazan crystals formed
was dissolved by adding 100 𝜇l/well of DMSO and the optical
density was measured using microplate reader (Power Wave
XS2 Biotek) at 570 nm.
2.6. Wound Healing Assay. The HeLa cells were seeded (5 ×
105 cells/well) in 24-well plates and left for 24 h, at 37∘C
in CO2 (5%) until 90% confluency [17]. Then, the adherent
cell layer was scratched with a sterile tip of pipette 200𝜇l.
Cell debris was removed by washing with PBS and the
cells were treated with the selected fraction (15 𝜇g/mL).
Photographs of thewoundswere obtained at 0 and 72 hours of
treatment using a microscope Axio Vert A1 FL (Carl Zeiss),
at 400x magnification, and the relative migration distance
was measured by the following formula:
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percentage of wound closure (%) = 100 × (𝐴 − 𝐵)
𝐴
, (1)
where 𝐴 corresponds to the width of cell wounds before
incubation and 𝐵 the width of cell wounds after incubation
[18].
2.7. Invasion and Migration Assay. Hela cells (2.5 × 104) were
plated on the chambers Matrigel coated transwell (8mm
pore-size) in 24-well plates. Inside the chambers 1mL of
DMEM (serum free) containing 15 and 25 𝜇g/mL of the
treatment was added whereas DMEM containing 10% SFB
was added outside of the chamber. Cisplatin (15 𝜇g/mL) was
used as control [19]. After 24 hours, cells that had degraded
the Matrigel and invaded to the lower surface of the Matrigel
coated membrane were fixed (methanol 70%) and stained
with Hematoxylin/Eosin. The cells were photographed (50x)
and counted. The same procedure was performed using the
plates without Matrigel to evaluate the migratory capacity of
the cells [15].
2.8. Western Blot Analysis. HeLa cells were treated for 24
hours at the concentrations of 15, 25, and 40 𝜇g/ml of FR3.
The dose choice was based on the IC
50
value calculation.
After that, the cells were lysed in a buffer containing 50mM
Tris pH 7, 150mM NaCl, 5mM EDTA, 1mM Na
3
VO
4
,
10mM NaF, 10mM sodium pyrophosphate, 1% NP-40,
and Protease Inhibitors containing 1mM Na
3
VO
4
, 10mM
NaF, 10mM sodium pyrophosphate, 1% NP-40, 10 𝜇g/ml
leupeptin, 10 𝜇g/ml aprotinin, 1mM DTT, 0.01M EDTA,
and 1mM PMSF. After electrophoresis, the proteins from
the gel were transferred (TE 70 PWR Semi-Dry Trans-
fer Unit, GE Healthcare) to a nitrocellulose membrane
(Amersham Protram supported 0.45 𝜇m NC, GE Health-
care) using a buffer with 25mM Tris, 193mM glycine, and
20% methanol. The expressions of the total and cleaved
Parp (# 4967), total and cleaved caspase-8 (# 9746), total
and cleaved caspase-3 (# 9662), FAS protein (# 4233), RIP
protein (# 4926), and tumor necrosis receptor 1 (TNF-R1)
(# 3736) were evaluated. All antibodies were diluted and
incubated, according to the manufacturer’s recommenda-
tions (1/1000 v/v). After washing with TBS-T, membranes
were incubated with the secondary anti-rabbit antibody
(# 7074) at 1 : 5000 (v/v) dilution.Then, the strip detectionwas
performed by chemiluminescence (ECL, Western Blotting
Detection Reagents, RPN2109; GE Healthcare, Piscataway,
NJ) using a 1 : 1 (v/v) dilution and subsequently the mem-
branes were photographed using ImageQuant LAS 4000
mini GE Healthcare). All experiments were performed in
triplicate.
2.9. ESI(−)FT-ICRMS. Fourier transform ion cyclotron reso-
nance mass spectrometry (FT-ICR MS) analysis was per-
formed using a mass spectrometer (model 9.4 T Solarix,
BrukerDaltonik GmbH, Bremen, Germany).The extract FR3
was analyzed by negative electrospray ionization, ESI(−),
which was infused at a flow rate of 4 𝜇Lmin−1 into the ESI
source. The ESI(−) source conditions were set as follows:
nebulizer gas pressure of 1.5 bar, capillary voltage of 3.9 kV,
transfer capillary temperature of 200∘C, and endplate offset
of −500V. The front and back trapping voltages in the
ICR cell were +0.80V and +0.85V, respectively. The ion
accumulation time in the hexapole was 0.010 s, followed by
transport to the analyzer cell (ICR) through the multipole
ion guide system (another hexapole). The mass spectra were
acquired by accumulating 64 scans of time-domain transient
signals in four mega-point time-domain data sets. The mass
spectrum was processed using the Compass Data Analysis
software package (BrukerDaltonics, Bremen, Germany). The
proposed molecules were assigned using the Chemspider
database (http://www.chemspider.com).The degree of unsat-
uration for each molecule was deduced directly from its
DBE value according to equation: DBE = 𝑐 − ℎ/2 +
𝑛/2 + 1, where 𝑐, ℎ, and 𝑛 are the carbon, hydrogen, and
nitrogen numbers, respectively, in the molecular formula
[20].
2.10. Statistical Analysis. Statistical analyses for single com-
parisons were performed by Student’s 𝑡-test, and the dif-
ferences between the groups were tested using the One
Way ANOVA multiple comparisons test using the GraphPad
Prims program version 7 𝑝 < 0.05. All results underwent the
Shapiro-Wilk normality test with 𝑝 > 0.05.
3. Results
3.1. FR3 Inhibits the Gelatinolytic Activity of MMP-2 and
MMP-9 In Vitro and Selectively Decreases the Viability of
Tumor Cells. We observed that FR3 was the only fraction
tested that completely inhibited MMP-2 and MMP-9 (Fig-
ure 1), standing out from the others. The FR3 reduced
HeLa cell viability in a dose-dependent manner (Figure 2).
Furthermore, at higher concentrations (25 and 50 ug/ml)
FR3 decreased HeLa cell viability (50.66 ± 6.02% and 21% ±
3.60, resp.) (IC
50
: 25𝜇g/mL) and showed lower toxicity to
nontumor PBMCs (87.33% ± 5.03 and 71% ± 10.81) at the
same concentrations.
3.2. FR3 Inhibits HeLa Cell Migration and Invasion and
the Presence of Active MMP-2 in the Cell Supernatant. FR3
significantly inhibited HeLa cell migration (Figures 3(a) and
3(b)) in the wound closure assay. FR3 showed greater efficacy
in HeLa cell transwell migration inhibition than Cisplatin
(Figure 3(c)) according to the number of cells counted
(Figure 4). Similarly, FR3 inhibitedHeLa cell invasion signifi-
cantly more than Cisplatin in theMatrigel assay (Figure 3(d))
according to the number of cells counted (Figure 4). Active
MMP-2 was not observed without supernatant from the
treated cells in which the control cell supernatant showed
a clear band corresponding to the activity of this enzyme
(Figure 3(b)).
3.3. FR3 Induces Apoptosis by the Extrinsic Pathway in HeLa
Cells. HeLa cell treatment with FR3 showed a significant
increase (206.2% ± 20.98, 40 𝜇g/mL) in cleaved caspase-8
expression (Figure 5(b)) and caspase-3c/caspase-3 (15, 25, and
40 𝜇g/mL) (Figure 5(d)).The caspases are a group of cysteine
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Figure 1: The gelatinolytic activity of MMP-2 and MMP-9 treated with the B. variegata candida fractions was inhibited by FR3 (a) when
treated for 3 hours of incubation, with a total decrease of the percentage of active gelatinases, significantly different from the other fractions
(b). ∗ ∗ ∗∗ represents the significant difference with a value of 𝑝 < 0.0001.
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Figure 2: Viability analysis (MTT) of PBMCs and HeLa cell line exposed to the FR3 (0.5; 10; 25; and 50 𝜇g/mL) for 72 hours.The results were
expressed in relation to the DMSO control. ∗ ∗ ∗∗ indicates statistically significant differences between treatment and control in the same
cell line. Different letters indicate statistically significant differences between each treatment between both cell lines (𝑝 < 0.0001).
proteases that regulate death mechanisms such as apop-
tosis.
The increase of expression of RIP (a receptor-interacting
protein 1, the DD-containing serine/threonine kinase, plays
a crucial role in switching between death and survival
signaling) and TNF-R1 (canonical death receptor essential
for TNF-induced apoptosis) (Figures 6(b) and 6(d)) and
decreased FAS expression (40 ug/mL) (Figure 6(c)) are also
observed, confirming that FR3 cytotoxicity against HeLa cells
was due to induction of cell death by apoptosis. The ratio
of PARPc/PARP expression showed no significant difference
(Figure 6(c)).
3.4. ESI(−)FT-ICR MS Analysis. Among the assigned com-
pounds in FR3 sample using ESI(−)FT-ICR MS, are the
ethyl a-D-glucopyranoside, D-pinitol, and fatty acids such as
palmitic acid, oleic acid, and phenolic acid.These compounds
are present in plant extracts with proven antitumor activities
(Table 1).
4. Discussion
In the present study, we showed that the Bauhinia variegata
candida fraction (FR3) inhibits the MMP-2 and MMP-9
gelatinolytic activity. We also demonstrated that this fraction
decreased HeLa cell viability and exhibited low toxicity in
normal cells. The migration and invasion decreased and
the amount of active MMP-2 in the HeLa cell supernatant
decreased. Moreover, we showed that exposure to FR3 induc-
ed cell death via TNFR-1 andRIP1. Finally,mass spectrometry
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Figure 3: FR3 inhibited wound closure of the HeLa cell monolayer after 72 hours of treatment (a) in 70% (𝑝 ≤ 0.05) and decreased the
expression of active MMP-2 in the supernatant of these cells (b). FR3 inhibited the migration of HeLa cells (15 ug/ml and 30 ug/ml) by the
Boyden Chamber assay, as well as treatment with Cisplatin (15 ug/ml) for 24 hours (c) and inhibited the invasion of HeLa cells treated for
24 hours using Matrigel (d). The significant difference with 𝑝 ≤ 0.05 values. ∗ ∗ ∗ indicates statistically significant differences between
treatment and control with value of p ≤ 0.001. ∗∗ indicates statistically significant differences between treatment and control with value of p
≤ 0.005. ∗ represents the significant difference with a value of p ≤ 0.05. Different letters indicate statistically significant differences between
each treatment with p ≤ 0.0001.
Table 1: Molecular formulas and compounds estimated from components present in FR3 by ESI(-)M.
Experimentalm/z Error (ppm) Proposed compounds Reference
207.08744 0.11 Ethyl a-D-glucopyranoside Ndongo et al., 2015
229.04849 0.20 D-Pinitol Tien-Huang et al., 2013
243.06412 0.13 Ethyl a-D-glucopyranoside -
255.23301 0.21 Palmitic acid Harada et al., 2002
281.24867 0.24 Oleic acid Harada et al., 2002
421.22677 0.5 Phenolic acid Chen et al., 2012.
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FR3 15 g/mL FR3 25 g/mL
CIS 15 g/mLControl
FR3 15 g/mL FR3 25 g/mL
CIS 15 g/mLControl
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Figure 4: FR3 decreased the number of cells that migrated through the Boyden Chamber in Migration and Invasion assay. 100x to magni-
fication.
showed that Bauhinia variegata candida fraction FR3 con-
tained glucopyranosides, D-pinitol, fatty acids, and phenolic
acid.
It is reported that some plant-derived compounds can
exhibit an inhibitory action against MMP-2 and MMP-9
gelatinolytic activity in vitro studies [21–23]. However, few
studies have interrogated the action of Bauhinia extractswith
inhibition of these enzymes. In a previous study conducted
by our group, Bauhinia ungulate extracts also inhibited the
activity of MMP-2 and MMP-9 [13]. Thus, it is believed
that species of the genus Bauhinia may contain promising
components with inhibitory action against MMPs. The FR3
presents as a promising compound for cancer treatment, as
it was selectively cytotoxic to the HeLa line. It is thought
that this activity is correlated with the presence of ethyl
a-d-glucopyranoside, already described in Bauhinia petran-
dra extracts [24] and belongs to a class of molecules that
has been highlighted by the antitumor activity of this cell
line [25, 26]. Another component of FR3 that may be
correlated with this activity is palmitic acid, which has
selective cytotoxic action on the MOLT-4 leukemia cell
line [27]. The FR3 is also considered promising because
it inhibits MMP-2 and MMP-9, enzymes that are closely
linked to dissemination [28] of a type of cancer considered
highly invasive and highly expressed in cervical cancer
[29].
Our results showed increased expression of TNFR-1
(tumor necrosis factor receptor), which is a membrane
receptor that interacts with FADD proteins (FAS-associated
death domain) and which, in turn, recruits caspase-8, which
cleaves caspase-3, triggering the cell death process extrinsic
pathway. Thus, since FR3 also provided for caspase-8 over-
expression, it is possible that the cytotoxicity evidenced in
the results is correlated with this cell death pathway [30].
However, intricately, death of HeLa cells may also be related
to the newly discovered necroapoptosis pathway, as the
results showed overexpression of RIPK1 (receptor-interacting
serine/threonine protein kinase 1), which is a protein present
in the necrosome, a characteristic structure of necroapoptosis
formed from the binding of TNF-𝛼 to its TNFR-1 ligand on
the cell surface [31]. Among the compounds found in FR3,
oleic acid, linoleic acid, and glucopyranoside can be corre-
lated with this activity, once they have already demonstrated
the activation of the extrinsic pathway of the HeLa lineage
[32].
Furthermore, it is believed that the decrease in MMP-
2 activity in the cell supernatant is linked to decreased
invasion and migration of HeLa cells, as several studies have
established a relationship between the in vitro antimeta-
static potential of plant extracts and the decrease in active
MMPs [33–35]. This can be explained by the fact that
MMPs act, via the degradation of the extracellular matrix,
through mechanisms that allow tumor growth, angiogenesis,
and metastasis [36]. D-pinitol, described as a component
of FR3, is believed to present some function in this con-
text, as it has already shown ability to inhibit cell migra-
tion, wound closure, and invasion of prostate cancer cells
[37].
In conclusion, the present study suggests that the mole-
cules present in the FR3 reduce cervical cancer cell viability.
Moreover, we demonstrated a reduction on themigration and
invasion activity. These finds can be correlated with MMPs
inhibitory activity.
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Figure 5: The FR3 acted on PARPc/PARP cell death marker proteins, caspase-3c/caspase-3, and caspase-8c/caspase-8 in 24-hour treated
HeLa cells. The concentrations used were 15𝜇g/mL, 25 𝜇g/mL, and 40 𝜇g/mL FR3 and 15 𝜇g/mL Cisplatin. (b)–(d) Densitometric analysis
of the western blot transfer data of the proteins. The significant difference with values of 𝑝 < 0.0001. Different letters indicate statistically
significant differences between each treatment with p ≤ 0.0001.
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Figure 6: Effect of the FR3 on RIP, FAS, and TNF-R1 in 24-hour treated HeLa cells at concentrations of 15𝜇g/mL, 25 𝜇g/mL, and 40 𝜇g/mL
andCisplatin at 15𝜇g/mL concentrations. (b)–(d) Densitometric analysis of the western blot transfer data of the three proteins.The significant
difference with values of 𝑝 < 0.0001. Different letters indicate statistically significant differences between each treatment with p ≤ 0.0001.
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